Key result
VO(OPT) attenuates pressure overload-induced cardiac hypertrophy and improves LV function in ovariectomized rats.
Why the study?
The cardioprotective effects and mechanisms of bis(1-oxy-2-pyridinethiolato) oxovanadium (IV) against pressure overload-induced cardiac hypertrophy in ovariectomized rats were unclear.
Does VO(OPT) improve myocardial hypertrophy and cardiac function in ovariectomized rats with pressure overload-induced hypertrophy?
Does VO(OPT) improve myocardial hypertrophy and cardiac function in ovariectomized rats with pressure overload-induced hypertrophy?
VO(OPT) attenuates cardiac hypertrophy and prevents progression to heart failure in a rat model of pressure overload and ovariectomy, mediated by Akt and eNOS activation.
Hypothesis-generating in estrogen-deficient pressure-overload models; human trials needed before any clinical consideration.
We here investigated the effect of bis(1-oxy-2-pyridinethiolato) oxovanadium (IV), [VO(OPT)], against myocardial hypertrophy and cardiac functional recovery in pressure overload-induced hypertrophy in ovariectomized female rats and defined mechanisms underlying its cardioprotective action. Wistar rats subjected to bilateral ovariectomy were further treated with abdominal aortic stenosis. VO(OPT) (containing 1.25 and 2.50 mg of vanadium per kg) was administered orally once a day for 14 days starting from 2 weeks after aortic banding. Treatment with VO(OPT) significantly inhibited pressure overload-induced increase both in the heart weight:body weight ratio and the lung weight:body weight ratio. VO(OPT) also attenuated hypertrophy-induced impaired left ventricular end-diastolic pressure, left ventricular developed pressure, and left ventricular contractility (+/-dp/dt(max)). VO(OPT) treatment significantly restored pressure overload-induced impaired endothelial NO synthase activity with concomitant increased phosphorylation of endothelial NO synthase (Ser1179). Moreover, VO(OPT) treatment significantly restored pressure overload-induced reduced Akt activity, as indicated by increased phosphorylation at Ser473 and at Thr308. Treatment with VO(OPT) also secondarily inhibited calpastatin and dystrophin breakdown and decreased myosin light chain phosphorylation. Finally, VO(OPT) treatment significantly attenuated mortality after repeated isoproterenol administration in pressure overloaded-ovariectomized rats. Taken together, VO(OPT) attenuates cardiac myocytes hypertrophy in vivo in pressure overload-induced hypertrophy in ovariectomized rats and prevents the process from hypertrophy to heart failure. These effects are mediated by inhibition of calpastatin and dystrophin breakdown in addition to increased Akt and endothelial NO synthase activities.
No takes yet. Share an insight, caveat, or question.
Bhuiyan et al. (2008) studied Pressure overload-induced hypertrophy. bis(1-oxy-2-pyridinethiolato) oxovanadium (IV) [VO(OPT)] was evaluated on Myocardial hypertrophy and cardiac functional recovery. VO(OPT) significantly attenuated pressure overload-induced cardiac hypertrophy, improved left ventricular function, and reduced mortality after repeated isoproterenol in ovariectomized rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: